Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of ...
Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several rating updates on January 8. Truist lifted the price target on the stock to ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teleflex (TFX – Research Report) and Biogen (BIIB – Research Report). Claim 50 ...
Biogen is expected to announce its fiscal fourth-quarter earnings soon, and analysts project a double-digit earnings drop.
Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are covering the firm, MarketBeat.com reports. Eighteen analysts have rated ...
If you are wondering whether Biogen’s current share price still offers value, or if the recent run has already priced in the ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...
StockStory.org on MSN
Unpacking Q3 earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) in the context of other therapeutics stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...
UCB SA (OTC:UCBJY) (OTC:UCBJF) (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results